QCG
XERS icon

Quadrant Capital Group’s Xeris Biopharma Holdings XERS Stock Holding History

Quadrant Capital Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-85
Closed – – 2593
2021
Q1 		$0 Hold
85
– – ﹤0.01% 2470
2020
Q4 		$0 Buy
+85
New +$425 ﹤0.01% 2387

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's XERS Position: Q2 2021 in Review

Quadrant Capital Group sold out of Xeris Biopharma Holdings (XERS) in Q2 2021, closing a stake of 85 shares.

Quadrant Capital Group first reported a position in XERS in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 93 funds tracked by Wall St. Rank hold XERS as of Q2 2021.

  • Quadrant Capital Group reported no remaining Xeris Biopharma Holdings position as of Q2 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 85 Xeris Biopharma Holdings shares in Q2 2021.
  • Quadrant Capital Group first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 2 quarters.
  • Quadrant Capital Group's Xeris Biopharma Holdings position peaked at $0 in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2021.

Based on Quadrant Capital Group's 13F filing for Q2 2021, filed 9 Aug 2021.